Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-06-20
2006-06-20
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S045000, C536S026700, C536S027140
Reexamination Certificate
active
07064112
ABSTRACT:
Adenosine receptor agonists, particularly an agonist which binds to the A3 adenosine receptor, are used for induction of production or secretion of G-CSF within the body, prevention or treatment of toxic side effects of a drug or prevention or treatment of leukopenia, particularly drug-induced leukopenias; and inhibition of abnormal cell growth and proliferation.
REFERENCES:
patent: 5688774 (1997-11-01), Jacobson et al.
patent: 5773423 (1998-06-01), Jacobson et al.
patent: 6048865 (2000-04-01), Baraldi
patent: 2 289 218 (1995-11-01), None
patent: 2071770 (1997-01-01), None
patent: 2071771 (1997-01-01), None
patent: WO 94/21195 (1994-09-01), None
patent: WO 95/02604 (1995-01-01), None
patent: WO 98/50047 (1998-11-01), None
patent: WO99/02143 (1999-01-01), None
patent: WO9902143 (1999-01-01), None
patent: WO 99/06053 (1999-02-01), None
patent: WO99/20284 (1999-04-01), None
patent: WO99/63938 (1999-12-01), None
patent: WO00/15231 (2000-03-01), None
patent: WO00/40251 (2000-07-01), None
patent: WO00/44763 (2000-08-01), None
patent: WO0107060 (2001-02-01), None
Enrique Rozengurt., Experimental Cell Research, vol. 139, (1982), pp. 71-78.
G. Sandberg et al., Thymus, vol. 3, (1981), pp. 63-75.
Michael G. Collis; Pharmac. Ther., vol. 41, (1989), pp. 143-162.
Luiz Belardinelli et al., Progress in Cardiovascular Diseases, vol. XXXII, No. 1 (Jul./Aug.), 1989, pp. 73-97.
R.B. Gilbertsen; Agents and Actions, vol. 22, 1/2 (1987), pp. 91-99.
Pnina Fishman et al.; Cancer Research, vol. 58, pp. 3181-3187, Jul. 15, 1998, pp. 3181-3187.
Raghvendra Dubey et al.; Circulation, 1997, 96:2656-2666.
U. Soderback et al.; Clinical Science; (1991), vol. 81, pp. 691-694.
Bernard Clarke et al.; International Journal of Cardiology, vol. 23, (1989), pp. 1-10.
Meir Djaldetti et al.; Clin. Exp. Metastasis, 1996, vol. 14, pp. 189-196.
Robert L. Stolfi et al.; Cancer Research, Feb. 1983, pp. 561-566.
Fernando A. Gonzalez; Proc. Natl. Acad. Sci. USA; vol. 87, pp. 9717-9721; Dec. 1990.
Maarteen G. Bouma et al.; Journal of Immunology, 1994, 153: 4159-4167.
Joel Linden; FASEB J. 5: 2668-2676; 1991.
Raghvendra K. Dubey et al.; Hypertension, 1998; 31 [part 2]: 516-521.
Sullivan et al.; Drug Development Research, vol. 45, No. 3-4, pp. 103-113, 1998.
Mittelman et al.; Annals New York Academy of Sciences, vol. 255, pp. 225-234, 1975.
Jacobson et al.; Apoptosis, vol., 4, No. 3, pp. 197-211, 1999.
Ramkumar et al., J. Biol. Chem., vol. 268, No. 23, pp. 16887-16890, 1993 (Abstract).
Sajjadi et al.; J. Immunology, vol. 156, No. 9, pp. 3455-3442, May 1, 1996 (Abstract).
Bouma et al.; J. Immunology, vol. 158, No. 11, pp. 5400-5408, Jun. 1, 1997 (Abstract).
Fishman et al., Drug Dev. Res., vol. 50, No. 1, May 2000, p. 101 (Abstract).
Journal of Cellular Physiology, vol. 183, No. 3, Jun. 2000, pp. 393-398.
Kohno et al.; Biochemical and Biophysical Research Communications, vol. 219, pp. 904-910, 1996.
M.E. Lesch et al., Agents and Actions, vol. 34, No. 1/2, (1991), pp. 25-27, XP-001028566.
Shib P. Dutta et al., Journal of Medicinal Chemistry, vol. 18, No. 8, (1975), pp. 780-783, XP-000653225.
Denis J. Schrier et al., The Journal of Immunology, vol. 145, No. 6, (Sep. 15, 1990), pp. 1874-1879, XP-001024527.
Gary W. Bong et al., J. Clin. Invest., vol. 98, No. 12, (Dec. 1996), pp. 2779-2785, XP-001035234.
Willena M. MacKenzie et al., Cancer research, vol. 54, (Jul. 1, 1994), pp. 3521-3526, XP-000601409.
George L. Tritsch et al., Cancer Biochem. Biophys., vol. 2, (1977), pp. 87-90, XP-001002040.
Richard J. Gualtieri et al., Exp. Hematol., vol. 14, (1986), pp. 689-695, XP-001035203.
Woo-Jung Kim et al., Korean J. of Pharmacology, vol. 31, No. 3, (1995), pp. 333-344, XP-001028606.
Vladimir Shneyvays et al., Drug Development Research, vol. 50, (2000), pp. 324-337, XP-000994767.
P. Fishman et al., European Journal of Cancer, vol. 36, (2000), pp. 1452-1458, XP-001035229.
Silvia D'Ancona et al., Anticancer Research, vol. 14, (1994), pp. 93-97, XP-000994765.
Vickram Ramkumar et al., The Journal of Biological Chemistry, vol. 268, No. 23, (Aug. 15, 1993), pp. 16887-16890, XP-001026481.
Fereydoun G. Sajjadi et al., The Journal of Immunology, vol. 156, (1996), pp. 3435-3442, XP-002916157.
P. Fishman et al., The American Association For Cancer Research, vol. 40, (Mar. 1999), pp. 677, XP-001030826.
Yutaka Kohno et al., Biochemical and Biophysical Research Communications, vol. 219, (1996), pp. 904-910, XP-001028266.
Yao Yao et al., Biochemical and Biophysical research Communications, vol. 232, No. 2, (1997), pp. 317-322, XP-001035137.
Kenneth A. Jacobson et al., Drug Development Research, vol. 45, (1998), pp. 113-124, XP-001035206.
Kenneth A. Jacobson et al., TiPS, vol. 19, (May 1998), pp. 184-191.
P. Fishman et al., Clinical Cancer Research, vol. 5, (Nov. 1999), XP-000993539.
N.I. Perevodchikova (Ed.) Handbook: Antitumor Therapy, Moscow, 1993, pp. 192 and 202.
“Meditsina” Handbook of Oncology, Moscow, 1964, p. 63.
Browdy and Neimark PLLC
Can-Fite Biopharma Ltd.
Lewis Patrick
LandOfFree
Pharmaceutical compositions comprising an adenosine receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions comprising an adenosine receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising an adenosine receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3661453